Purpose The LipidCardio Study was established for in-depth analyses of cardiovascular risk factors, providing well-defined cardiovascular and metabolic phenotypes. Particularly the role of lipoproteins in the pathobiological process and treatment of cardiovascular disease will be a main focus.
Introduction
Ischemic heart disease accounts for > 20% of all deaths in Europe. [1] Although ageadjusted mortality rates from coronary artery disease (CAD) have declined substantially in the past decades throughout Europe and the US, the incidence and prevalence of CAD remain high. [2, 3] Accordingly, 27% of all disability-adjusted life years (DALYs) in Germany are due to coronary artery disease. [1] It is well established that traditional modifiable risk factors for CAD (hypertension, hypercholesterolemia, sedentary lifestyle, obesity smoking, and diabetes) predict the risk of developing CAD, and targeting them decreases cardiovascular risk in a dosedependent manner. [4] However, among patients with prevalent CAD, it has been shown that there is substantial variation in estimated 10-year risk of outcomes, with a large proportion of individuals with a 10-year risk <10%, but also a considerable proportion with very high residual risk despite optimally controlled risk factors. [5] Therefore, the identification and consideration of additional modifiable risk factors to reduce (residual) cardiovascular risk is crucial, and novel biomarkers, and assessment of the individual genetic profile bear the potential of improving risk assessment for primary and secondary prevention. Since patients with prevalent CAD are a very heterogeneous group, discrimination is likely to be advantageous over a one fits all disease management strategy.
Dyslipidemia is a major cause of atherosclerotic cardiovascular disease. In addition to low density lipoprotein cholesterol (LDL-C), lipoprotein (a) [Lp(a)] has emerged as an independent risk factor for CAD. [6] Whereas the causal role of LDL-C is well established, Lp(a) is less well understood and still a subject of controversy. [6, 7] The underlying physiological function of this lipoprotein is still unknown. Several studies have indicated that serum/plasma Lp(a) is largely genetically determined, and there is strong suggestion that Lp(a) is causally associated with CAD. [8] Prospective observational studies have shown that Lp(a) was an independent risk factor for major adverse cardiovascular events (MACEs), i.e. the progression of CAD in patients with stable CAD who received optimal medical therapy, and that Lp(a) levels were positively associated with coronary lesion severity as well. [7, 9] Screening for elevated Lp(a) presently is recommended in those at intermediate or high CV risk, in particular as an additional risk indicator. [7, 10, 11] Moreover, Lp(a) has been suggested as a potential therapeutic target. [12] To note, an antisense oligonucleotide specific to apo(a) has been recently shown to lead to dose-dependent reductions in average Lp(a) levels of >80%. [13] Overall, substantial progress has been made in the field of CAD in the last decades.
However, further improvements will presuppose careful characterization of different phenotypes and subsequent joint application of genetics, epigenetics and metabolomics. For this purpose we established the LipidCardio Study in 2016. We sought to implement detailed phenotyping and follow-up of patients with different severity of CAD and also without obstructive CAD to examine factors associated with the pathobiological process and progression of CVD. There will be a strong focus on lipoproteins and genetics. In particular, we seek to gain further insight into the role of Lp(a) in cardiovascular pathogenesis and to investigate the implications of a screening for Lp(a) in a high risk cohort of patients undergoing cardiac catheterization and coronary angiography. Combining phenotype factors with genetic factors, we desire to elaborate the particular cardiovascular risk profile of patients with high Lp(a).
As another integral part of this study we collected ample blood specimens to hold highquality, well-characterized biomaterials along with their clinical, genetic, and demographic information for future biomedical research projects in store in a highquality biobank. The main study variables are shown in Supplementary Table 1 . A comprehensive data collection was performed, with a strong focus on cardiovascular health. Blood specimens were collected at the time of cardiac catheterization (after administration of heparin), either as arterial blood sample directly from the radial or femoral artery sheath or as a venous blood sample from a peripheral intravenous access. At enrolment, patients were interviewed to collect information on demographic characteristics, overthe-counter (OTC) medication usage, health behaviors (alcohol/drug use, smoking, physical activity), a detailed standardized family history was obtained, and a screening test for cognitive impairment (the mini-mental state examination, (MMSE) was performed. Information on regular prescription medications were obtained from the patients' medication plan. In addition, electronic medical records were reviewed by study personnel to obtain previous diagnoses of chronic conditions, as well as to document previous angiographic findings and coronary revascularization history.
Cohort description
Portions of the blood specimens were used to determine a basic panel of laboratory tests essential to this study. Lp(a) was determined using a turbidimetric assay (Roche Diagnostics GmbH, Mannheim). Lp(a) is given in nmol/L, correctly reflecting the number of Lp(a) particles. [14] A range of other parameters were taken over from the hospital information system (HIS), provided that they were ordered as part of the clinical routine. Importantly, all tests were done in one central, accredited laboratory.
Specimens
EDTA blood samples were frozen immediately following collection at -80°C until DNA was isolated using the sbeadex livestock kit (LGC Genomics GmbH, Germany).
Selected SNPs were genotyped using KASP chemistry (LGC, Hoddesdon, UK).
Additional blood samples were drawn and stored in the Central Biomaterial Bank
Charité (ZeBanC) [15] , providing the opportunity for additional measurements at a later date.
Coronary angiography
Cardiac catheterization and coronary angiography were performed according to the standard protocols of the Interventional Cardiology Unit and by discretion of the interventional cardiologist. The interventional cardiologist routinely documented diagnostic findings. Comprehensive angiographic results at the time of enrolment were recorded in the study database.
Echocardiography, blood pressure measurement, pulse wave analysis Echocardiography was performed as a part of the clinical routine, and selected parameters were taken over into the study database.
Blood pressure was measured once on each arm, in a sitting position and at rest with a boso medicus uno device with an adequate cuff size.
Central blood pressure, pulse wave reflection, and pulse wave velocity were measured with the Mobil-O-Graph PWA device, according to the operating instructions of the manufacturer.
Other measurements
Waist circumference was measured at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest. Hip circumference was measured around the widest portion of the buttocks, with the tape parallel to the floor. For both measurements, the subjects were standing and wore little clothing. [16] Hand grip strength was measured with a Smedley Dynamometer (Saehan, Type SH5002).
Questionnaires
The Seattle Angina Questionnaire, and the Rapid Assessment of Physical Activity (RAPA) questionnaire were administered. Folstein's Mini-Mental State Examination (MMSE) for screening of cognitive impairment was administered in face-to-face interviews by trained study personnel.
Planned follow-up measures
Mortality information will be obtained from the obligatory registry office in two-year intervals. Follow-up phone interviews will be conducted by trained study personnel, and the calls are planned to be made at 3, and 6 years after initial enrolment. Adverse CVD events, including non-fatal MI, acute coronary syndromes, heart failure, hospitalizations, cardiac procedures (e.g., revascularization), strokes and peripheral arterial disease events will be recorded. Additional information will be collected on follow-up coronary angiogram data, development of comorbidities (hypertension, diabetes, cardiac arrhythmia, valvular heart disease, obstructive sleep apnoea and cancer) and changes in medications.
Findings to date
The cohort Those with evidence of obstructive CAD were significantly more likely to have a positive family history of cardiovascular disease (odds ratio (OR) 1.48, 95% confidence interval (CI) 1.06 to 2.06, p=0.019), compared to participants with no apparent CAD.
Likewise, participants with obstructive CAD were significantly more likely to be physically inactive (OR 1.50, 95% CI 1.09 to 2.16, p=0.014).
Lipoprotein(a)clinical and genetic associations
The median serum concentration of Lp(a) at baseline was 19. 
Genetic associations
In order to assess if our cohort data are suitable for genetic association analyses, we genotyped and examined LPA-SNPs rs10455872, rs3798220 and rs186696265, which have been previously reported to be strongly associated with Lp(a) serum levels. [18] [19] [20] [21] Overall 179 patients (18.8%) were carriers of at least one minor allele. All three SNPs were significantly associated with Lp(a) levels in the LipidCardio cohort ( Table  3 ). The strongest evidence of an association with Lp(a) serum levels was found for rs10455872 (β=0.794; p= 5.1×10 -52 , Table 3 and Figure 1 ). Our data were compatible with an overall positive association (OR 1.35; 95 % CI 0.93-1.99, p=0.118) between carrying a minor LPA variant and CAD; even though the evidence was week. However, when stratified by sex there was reasonable evidence to suggest an association between the LPA-SNPs tested and obstructive CAD in women (OR 1.85, 95%CI 1.02-3.35, p=0.04), while in men there was no evidence for such an association. The association in women was stable even after adjusting for age, type 2 diabetes, LDL-C, and statin therapy. Furthermore, we genotyped the two SNPs rs429358 and rs7412 constituting the three APOE isoforms apoE2, apoE3, and apoE4. Rs7412 was recently confirmed in a large GWAS (meta-analysis) to be associated with Lp(a) serum levels with genome wide significance. [18] Indeed, we found rs7412 to be significantly associated with Lp(a) concentration (β=0.15; p= 0.008), i.e. we could replicate the previous finding. Similar to the earlier study, there was no evidence that rs429358 was also associated with Lp(a) serum levels in the LipidCardio cohort (data not shown), while there was reasonable evidence of an association between the inferred APOE isoforms (Supplementary Table 2 ) and Lp(a) serum levels (β=0.015; p= 0.006, N=893) (see Supplementary Table 2 ). 
Strengths and limitations of this study
-Most importantly, this cohort has coronary angiographic information on all included subjects. Thus, while the majority has confirmed obstructive CAD, we can ensure that the unaffected "comparison group" effectively has no apparent CAD.
-In addition we are able to differentiate a group with non-obstructive CAD, constituting an interesting intermediate group. This differentiation is particularly important in terms of distinct phenotypes.
-A potential weakness is that patients are only recruited from one tertiary care hospital.
Therefore, the results may not be generalizable to other patients with CAD.
Collaboration
We are interested to share data and biobank samples with other researchers in joint collaborative projects, e.g. for replication of phenotypic and/or genetic findings or metaanalyzes of study results. Interested groups should contact the study coordinating PI Ilja Demuth at ilja.demuth@charite.de for the data-sharing application form. Each application will be reviewed by the LipidCardio PIs (currently I.D., U.L. and E.S-T.) and
the decision communicated to the applicants usually within 6 weeks of submission.
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